Rapport Therapeutics Shares Drop Following Announcement of $355 Million Capital Raise
Rapport Therapeutics (RAPP) experienced a significant premarket decline of 24% after announcing a multi-layered financing strategy. The clinical-stage biotechnology company plans to raise approximately $175 million through common stock offerings, alongside a $150 million issuance of convertible senior notes due in 2032. In addition to the public offerings, the company is conducting a separate $30 million private placement of common stock. This substantial influx of capital aims to fund ongoing clinical operations but has triggered immediate selling pressure as investors react to the potential dilution and debt obligations.